Atomoxetine – further delay in change of funded brand and open access

Update Medicines

PHARMAC is advising all interested parties that there is a further one-month delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions. The following reflects the most up-to-date information.

The listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg) has been further delayed and will now be listed from 1 July 2020. The restrictions will be removed from atomoxetine from that date. The current funded brand, Strattera, will remain listed until 1 December 2020.

May 2020 update

Generic Partners has advised PHARMAC of ongoing delays in supplying its brand of atomoxetine due to manufacturing issues. As a result, the listing date in Section B and Part II of Section H of the Pharmaceutical Schedule for all strengths will be moved to 1 July 2020, and the Special Authority and the Hospital Indication Restriction for atomoxetine will now be removed from 1 July 2020.

This also means the subsidy reduction in Section B for the currently funded Strattera brand will now occur from 1 September 2020. The Strattera brand will be delisted from Part II of Section H of the Pharmaceutical Schedule (hospital listing) on 1 September 2020 and from Section B (community listing) from 1 December 2020.

Generic Partners will be the sole subsidised brand from 1 December 2020 in the community until 30 June 2022 and will be the Hospital Supply Status brand of atomoxetine until 30 June 2022, with a 1% DV Limit.

A Brand Switch Fee will apply to Generic Partners’ brand for the period of 1 December 2020 until 1 March 2021. 



Generic Partners atomoxetine listed in Schedule (Sections B and H)

1 July 2020

Special Authority criteria removed (Sections B and H)

1 July 2020

Hospital sole supply

1 September 2020

Subsidy reduction for currently funded Strattera brand (reference pricing)

1 September 2020

Community sole supply

1 December 2020

Delisting of Strattera from Section B

1 December 2020

Brand switch fee applies for Generic Partners

1 December 2020 to 1 March 2021 

The details 

The decision to fund the Generic Partners’ brand of atomoxetine was the result of a Request For Tender issued in August 2018.

> Read the Request for Tender

This change was the subject of a consultation letter dated 10 December 2018 and the subsequent decision was notified on 31 January 2019.

> Read the consultation 

> Read the original notification

It was originally communicated that the Generic Partners’ brand of atomoxetine would be funded from 1 July 2019 and all funding restrictions would be removed from atomoxetine at the same time. Generic Partners advised PHARMAC of a delay in supporting its brand of atomoxetine which was notified most recently on 10 January 2020.

Who to contact

If you have any questions about this notification, you can email us at; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.